In a mouse model of RA, treatment with Tofacitinib, which inhibits JAK1 and JAK3, and to a lesser extent JAK2 and TYK2, altered the levels of IL-17 and γδ17 T cells while promoting the presence of γδ T regulatory cells (125). Here, IL17A is linked to rheumatoid arthritis.